Exchange factor directly activated by cAMP 2 (EPAC2) (EPAC2)

Exchange factor directly activated by cAMP 2 (EPAC2), also known as RAPGEF4, is a multidomain protein that serves as a critical intracellular sensor for cyclic AMP (cAMP), operating independently of the classical protein kinase A (PKA) pathway (UniProt Q9Y266). It is predominantly expressed in the pancreas, brain, and adrenal glands, where it regulates vital processes such as glucose-stimulated insulin secretion and neurotransmitter release (PubMed: 11884611). EPAC2 functions by activating small GTPases Rap1 and Rap2, which subsequently modulate cytoskeletal dynamics and exocytotic machinery (PubMed: 12606328). In clinical contexts, EPAC2 is a significant target for type 2 diabetes research because it mediates the effects of incretin hormones like GLP-1 on insulin release (PubMed: 21964404). Furthermore, genetic variants in the RAPGEF4 gene have been associated with autism spectrum disorders, suggesting a role in synaptic plasticity and brain development (PubMed: 18463636). Therapeutic strategies targeting EPAC2 include the development of small-molecule agonists to enhance insulin secretion and antagonists to study its role in various pathologies, though achieving isoform selectivity remains a primary pharmacological hurdle (PubMed: 23623554).

Other names

RAPGEF4cAMP-regulated guanine nucleotide exchange factor IIcAMP-GEFIIRap guanine nucleotide exchange factor 4

EPAC2 acts as a guanine nucleotide exchange factor (GEF) for Rap1 and Rap2 GTPases, facilitating the exchange of GDP for GTP upon binding of cAMP (UniProt Q9Y266). This activation triggers downstream signaling cascades that regulate exocytosis, particularly insulin granule release in pancreatic beta cells via interactions with Rim2 and Piccolo, and modulates synaptic strength in the central nervous system (PubMed: 11884611, PubMed: 18463636).